Skip to content

Effects of Endotoxin Absorption and Cytokine Removal Hemofilter on Severe Septic Shock

Effects of Endotoxin Absorption and Cytokine Removal Hemofilter on Patients With Severe Septic Shock

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03974386
Enrollment
12
Registered
2019-06-04
Start date
2019-07-01
Completion date
2020-08-20
Last updated
2021-03-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sepsis, Severe, Septic Shock

Keywords

critical care, septic shock, hemofiltration, endotoxin, cytokine storm, prognosis

Brief summary

In recent years, many studies have pointed out that bacterial toxin and cytokine storm are the main causes of shock and multiple organ failure in patients with sepsis. Endotoxin is the main vehicle for systemic inflammatory reaction caused by gram-negative bacteria which induce sepsis. Endotoxin binds to Toll- Like receptor 4 (TLR4) trigger a cytokine storm. The amount of endotoxin is associated with shock, insufficient intestinal perfusion, and poor prognosis. Therefore, clinicians try to use various methods to antagonize the action of endotoxin, which can reduce the cytokine storm and inflammatory response to improve the prognosis of sepsis. Continuous venous venous hemofiltration plays a role in blood purification in septic shock. With different hemofiltration filters, it has different effects. By removing the inflammatory mediators caused by bacterial toxins and cytokines, shock can be improved. The study plans to receive patients with septic shock and use a hemofiltration filter that adsorbs endotoxin and removes cytokines (oXiris, Baxter Healthcare) to perform continuous venous venous hemofiltration in addition to basic septic shock resuscitation. The effect on the concentration of cytokines in the blood, the infusion dose of inotropics, the fluid balances, and the degree of organ damage was evaluated. It is hoped that the results of this pilot study can lead us to subsequent randomized clinical trials to explore whether this filter can improve the prognosis of septic shock patients.

Interventions

DEVICEoXiris blood purification set

Continuous venovenous hemofiltration and adsorption (CVVHA) with oXiris filter for up to 72 hours if required. The filter will be replaced every 24 hours. The setting of CVVHA is as follows: blood flow rate 200 mL/min, replacement fluid rate 2000 mL/hr, pre-dilution 50% and post-dilution 50%. If continuous renal replacement therapy is indicated after 72 hours, conventional hemofiltration filters will be used.

Sponsors

National Taiwan University Hospital
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients who meet all criteria (A+B+C): * A) Identified infection source under adequate treatment * B) Sepsis (the sequential organ failure assessment score rise 2 points or more) * C) Severe septic shock (serum lactate \> 2 mmol/L; need continuous norepinephrine infusion to maintain adequate blood pressure, of which dosage is \> 0.2 mcg/kg/min for more than 1 hour or \>0.1 mcg/kg/min for more than 3 hours )

Exclusion criteria

* Onset of severe septic shock more than 24 hours * Received continuous renal replacement therapy within 24 hours before enrollment * Serum white blood cell count count \< 1000 cells/μL or Platelet count \< 50000 cells/μL * History of allergy to heparin * Received cardiopulmonary resuscitation within 4 weeks before enrollment * ICU admission due to severe septic shock within 2 months * Patients or Family had chosen palliative care and signed an agreement to deny aggressive treatment * Pregnancy * APACHE II Score \> 30 at enrollment * Non-native speakers

Design outcomes

Primary

MeasureTime frameDescription
Difference of serum interleukin-6 level24 hoursComparison to enrollment or between 2 groups

Secondary

MeasureTime frameDescription
Difference of serum interleukin-1β level24 hoursComparison to enrollment or between 2 groups
Difference of serum interleukin-10 level24 hoursComparison to enrollment or between 2 groups
Difference of serum procalcitonin level24 hoursComparison to enrollment or between 2 groups
Difference of mean arterial pressure24 hoursComparison to enrollment
Difference of cardiac output24 hoursComparison to enrollment
Difference of serum interleukin-6 level48 hoursComparison to enrollment or between 2 groups
Difference of the sequential organ failure assessment score24 hoursComparison to enrollment or between 2 groups
Difference of serum endocan level24 hoursComparison to enrollment or between 2 groups
Difference of serum diamine oxidase level24 hoursComparison to enrollment or between 2 groups
Difference of daily IV fluids24 hoursComparison between 2 groups
Difference of norepinephrine infusion rate24 hoursComparison to enrollment

Countries

Taiwan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026